Vemurafenib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), HAS (France) and NICE (England), among others, recommended or restricted vemurafenib, while TLV (Sweden) did not recommend it.
The file has been open for more than a decade: 12.5 years separate the first record, 6 Feb 2012 at AWMSG (Wales), from the most recent, 15 Aug 2024 at PHARMAC (New Zealand).
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
3 distinct indication wordings are recorded for vemurafenib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 9 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess vemurafenib, on 6 Feb 2012; PHARMAC (New Zealand) did not open a file until 15 Aug 2024 — an unusually long tail of 12.5 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 4 of 9 dated records fall in 2012 alone.
Restriction is doing real work here: 2 of 8 decisive outcomes narrowed vemurafenib to a subgroup rather than accepting or refusing it outright, at NICE (England) and SMC (Scotland).
HAS (France) is the only agency to have returned to vemurafenib, recording 2 separate entries.
8 of the 18 agencies in this archive hold a record for vemurafenib.
The full ledger for vemurafenib reads 5 recommended, 2 restricted, 1 not recommended and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 15 Aug 2024 | Melanoma, Stage IIIC/IV with BRAF V600 mutation | PTAC advice: Medium · decision reached | source |
| HAS (France) | 23 Sep 2020 | Re-assessment of SMR and ASMR | SMR substantial · ASMR V | source |
| PBAC (Australia) | 2017 | Unresectable Stage III or Stage IV malignant melanoma | The PBAC recommended the listing of vemurafenib monotherapy for the treatment of patients … | source |
| G-BA (Germany) | 6 Mar 2014 | Zelboraf — benefit assessment §35a | added benefit: considerable (indication) | source |
| SMC (Scotland) | 9 Dec 2013 | As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. | accepted (restricted) | source |
4 further decisions for vemurafenib, across 4 agencies, are not shown here. They link to 3 further source documents.
Related molecules
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
Coverage: 9 decisions for vemurafenib from 8 agencies, 2012 to 2024. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.